Surrozen surges on earlier-than-expected start to human clinical trials

Surrozen

18/05/2022 17:50

** Shares of biotech  SRZN.O  jump as much as 21% to $2.99;
among top pct gainers across U.S. exchanges
    ** SRZN says it has dosed the first volunteer in its
early-stage trial for bowel disease treatment SZN-1326, starting
its first-ever human clinical trials about one quarter earlier
than planned  urn:newsml:reuters.com:*:nGNX3KLzvq
    ** SZN-1326 is co's investigational treatment targeting
moderate-to-severe ulcerative colitis
    ** Stock has fallen ~62% YTD through last close

 (Reporting by Ruhi Soni in Bengaluru)
 ((Ruhi.Soni@thomsonreuters.com
Twitter: https://twitter.com/ruhithere))